Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PPOX | P50336 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 7/20 | 0.47 |
| ▸ | MAOB | P27338 | 7/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22525915 | 0.92 | CASP3 (0.50) | LMNAHPGDGFERHSD17B10PPOX | |
| SCHEMBL22525914 | 0.90 | CASP3 (0.53) | LMNAHPGDGFERHSD17B10PPOX | |
| SCHEMBL12219880 | 0.86 | HPGD (0.47) | LMNAHPGDGFERHSD17B10PPOX | |
| SCHEMBL9151953 | 0.84 | PPOX (0.47) | HPGDGFERHSD17B10PPOXKDM4E | |
| SCHEMBL25467807 | 0.83 | HPGD (0.49) | LMNAHPGDGFERHSD17B10PPOX | |
| SCHEMBL25467809 | 0.82 | HPGD (0.48) | LMNAHPGDGFERHSD17B10PPOX | |
| SCHEMBL12386903 | 0.81 | POLB (0.54) | HPGDHSD17B10PPOXKDM4EALDH1A1 | |
| SCHEMBL24721730 | 0.81 | RXRA (0.50) | LMNAHPGDPPOXKDM4EALDH1A1 | |
| SCHEMBL13160119 | 0.78 | LMNA (0.60) | LMNAHPGDGFERHSD17B10KDM4E | |
| SCHEMBL30393735 | 0.78 | LMNA (0.60) | LMNAHPGDGFERHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20220332970-A1 | PHOTOSENSITIVE COMPOSITION, FILM, OPTICAL FILTER, SOLID-STATE IMAGING ELEMENT, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2022-10-20 | — | — | US | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3795570-A1 | SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | Accutar Biotechnology Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-10005787-B2 | Highly photo-stable bis-triazole fluorophores | NITTO DENKO CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | GENENTECH, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | SHIONOGI & CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | LMNA 4214/4885HPGD 2003/4885GFER 4509/4885 |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | LMNA 4186/4885HPGD 1831/4885GFER 4247/4885 |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | LMNA 938/4885HPGD 1892/4885GFER 4494/4885 |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | LMNA 1551/4885HPGD 1636/4885GFER 4786/4885 |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | LMNA 938/4885HPGD 1892/4885GFER 4494/4885 |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | MMP13, MMP3, MMP26 | LMNA 757/4885HPGD 2890/4885GFER 1277/4885 |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | LMNA 1792/4885HPGD 1434/4885GFER 4687/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | LMNA 3004/4885HPGD 556/4885GFER 3743/4885 |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | LMNA 2256/4885HPGD 1681/4885GFER 4497/4885 |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F5 | LMNA 159/4885HPGD 4120/4885GFER 2215/4885 |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | NISCH, BRSK1, BLK | LMNA 4073/4885HPGD 3061/4885GFER 2172/4885 |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | LMNA 4214/4885HPGD 2003/4885GFER 4509/4885 |
| US-10005787-B2 | Highly photo-stable bis-triazole fluorophores | CBR3, TPD52L2, TNS4 | LMNA 3388/4885HPGD 2223/4885GFER 1329/4885 |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | LMNA 3549/4885HPGD 286/4885GFER 2032/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | LMNA 1940/4885HPGD 718/4885GFER 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.